Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 0.81 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2697261 | 0.90 | MET (1.00) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL10242531 | 0.86 | MET (0.61) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL10242522 | 0.85 | MET (0.84) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL10242535 | 0.84 | MET (0.59) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL10242539 | 0.83 | MET (0.57) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL10242543 | 0.83 | MET (0.57) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL19191420 | 0.76 | MET (0.72) | METNPC1RAB9APDE3BPDE3A | |
| SCHEMBL9910486 | 0.76 | MET (0.72) | METNPC1RAB9APDE3BPDE3A | |
| SCHEMBL9910487 | 0.76 | MET (0.72) | METNPC1RAB9APDE3BPDE3A | |
| SCHEMBL9910484 | 0.76 | MET (1.00) | METNQO2PDE3BPDE3APIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885NPC1 287/4885POLB 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.